Amundi Grifols Sa Transaction History

Amundi

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$6.27 - $7.7 $270,105 - $331,708	-43,079 Reduced 40.72%	62,712 $395,000
Q1 2024 May 15, 2024	BUY	$5.47 - $11.38 $42,518 - $88,456	7,773 Added 7.93%	105,791 $706,000
Q4 2023 Feb 14, 2024	SELL	$7.71 - $11.56 $114,925 - $172,313	-14,906 Reduced 13.2%	98,018 $1.13 Million
Q3 2023 Nov 14, 2023	BUY	$8.91 - $10.91 $954,162 - $1.17 Million	107,089 Added 1835.29%	112,924 $1.03 Million
Q2 2023 Aug 14, 2023	BUY	$7.14 - $9.29 $8,610 - $11,203	1,206 Added 26.05%	5,835 $53,000
Q1 2023 May 15, 2023	BUY	$6.65 - $10.69 $6,630 - $10,657	997 Added 27.45%	4,629 $34,000
Q4 2022 Feb 14, 2023	BUY	$5.96 - $8.53 $20,818 - $29,795	3,493 Added 2512.95%	3,632 $30,000
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $827 - $1,987	139 New	139 $1,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.